WO2005097155A1 - Agent induisant un allongement de neurite - Google Patents

Agent induisant un allongement de neurite Download PDF

Info

Publication number
WO2005097155A1
WO2005097155A1 PCT/JP2005/006640 JP2005006640W WO2005097155A1 WO 2005097155 A1 WO2005097155 A1 WO 2005097155A1 JP 2005006640 W JP2005006640 W JP 2005006640W WO 2005097155 A1 WO2005097155 A1 WO 2005097155A1
Authority
WO
WIPO (PCT)
Prior art keywords
sugar chain
glcnac
sugar
residue
formula
Prior art date
Application number
PCT/JP2005/006640
Other languages
English (en)
Japanese (ja)
Inventor
Jianguo Gu
Masaki Shigeta
Naoyuki Taniguchi
Original Assignee
Takara Bio Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Bio Inc. filed Critical Takara Bio Inc.
Priority to JP2006512076A priority Critical patent/JPWO2005097155A1/ja
Publication of WO2005097155A1 publication Critical patent/WO2005097155A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the present invention relates to a sugar chain having a neurite elongation effect, a complex saccharide, a derivative of the sugar chain or the complex saccharide, a pharmacologically acceptable salt of the sugar chain or the complex saccharide, or a pharmaceutically acceptable salt thereof.
  • the present invention relates to an enzyme involved in sugar chain synthesis and a pharmaceutical composition, reagent, food or beverage containing a nucleic acid encoding the enzyme as an active ingredient.
  • Nerve cells usually construct a complex network by extending one axon and a plurality of ⁇ processes and exchanging signals with other cells.
  • a series of substances called neurotrophic factors play an important role in maintaining neuronal cell functions such as survival of neurons, differentiation of immature neuroblasts into mature neurons, neurite outgrowth, etc. Is believed to be.
  • ALS amyotrophic lateralsclerosis
  • MS multiple sclerosis
  • peripheral nervous system and central nervous system diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease includes methods to promote the survival and repair of damaged nerve cells (preservation regeneration) and neuronal cells. It is roughly classified into a method of replenishing cells capable of differentiating into cells (for example, neural stem cells) at the site of injury and recovering function (replenishment regeneration). Among them, the above-mentioned replenishment regeneration has not yet become widespread due to difficulties in obtaining cells to be replenished and ethical problems.
  • the preservation regeneration is, more specifically, a method of restoring function by regenerating axons from remaining nerve cells and forming new synapses.
  • nerve growth factor nerve growth factor
  • BDNF brain-derived neurotrophic factor
  • neurotrophin 3 neurotrophin-4Z5 and the like have been found.
  • nerve growth factors nerve growth factor, NGF
  • BDNF brain-derived neurotrophic factor
  • neurotrophin 3 neurotrophin-4Z5 and the like have been found.
  • Patent Document 1 reports a neurotrophic factor having a molecular weight of 60,000 5,000 and a neurotrophic factor having a molecular weight of 120,000 5,000 obtained from a culture medium for astrocytoma, glial cells or Schwann cells.
  • the neurotrophic factor described in the powerful Patent Document 1 has a neuroblastoma growth inhibitory activity and has a survival activity or a neurite outgrowth effect on nerve cells.
  • Patent Document 2 reports a glycosaminodalican derivative having a neurite outgrowth action with low anticoagulant activity.
  • low-molecular-weight neurotrophic factors include, for example, a neurite elongation agent containing a polyalkoxyflavonoid extracted from Rutaceae plants (Patent Document 3), a nerve cell proliferation action and a neurite extension action.
  • a cyclohexenol derivative (Patent Document 4) and a neurite outgrowth agent containing a pyrrolidine derivative or a piperidine derivative exhibiting a nerve cell growth promoting action Patent Document 5 have been reported. However, at present, these substances are not sufficiently effective.
  • Patent document 1 JP-A-07-101990
  • Patent Document 2 JP-A-11-310602
  • Patent Document 3 JP 2002-060340A
  • Patent Document 4 JP 2001-089404 A
  • Patent Document 5 Japanese Patent Laid-Open No. 2001-247569
  • Non-Patent Document 1 "Nature”, Vol. 344, 339-341 (1990) Disclosure of the Invention
  • the present invention relates to a novel neurite outgrowth agent, a therapeutic or preventive agent for neurodegenerative disease, a food or drink for treating or preventing the disease, and a nervous elongation effect which exerts a neurite outgrowth effect.
  • a method for inducing process elongation a method for treating or preventing a neurological disease, a method for improving or improving learning and Z or memory ability, a method for using a sugar chain for the manufacture of a medicament for treating or preventing a neurological disease, and a method for learning and preventing.
  • the present invention relates to providing a neurite outgrowth inducing agent that enables a new neural network to be formed based on neurite outgrowth.
  • the present invention relates to providing a therapeutic or preventive agent for a neurological disease, which is capable of ameliorating the symptoms of a disease associated with neurodegeneration, suppressing the onset or progression of the disease, and the like.
  • the present invention provides a learning, which allows for the enhancement of the learning and Z or memory capacity of an individual animal, the learning and recovery of the Z or memory capacity of an individual that has been reduced by various factors, and the like. And Z or providing a memory improver or improver.
  • the present invention relates to the provision of a food or beverage which, when ingested, can provide a therapeutic or preventive effect for a neurological disease, and an effect of improving or improving learning and Z or memory ability.
  • the present invention relates to providing a method of inducing neurite outgrowth, which allows for the generation of neurites that differentiate into axons or neurites and to induce Z or elongation, and the like.
  • the present invention provides a method for treating or preventing a neurological disease, which is capable of improving symptoms of a disease accompanied by neurodegeneration, suppressing the onset or progression of the disease, and the like.
  • the present invention provides a learning and Z or memory function that enables the learning and Z or memory capacity of an individual animal to be extended, the learning and the z or memory capacity of the individual to be reduced due to various factors, and the like.
  • the first invention of the present invention relates to a sugar chain having bisecting GlcNAc, a complex saccharide having the sugar chain in its structure, the sugar chain or a derivative of the complex sugar, the sugar chain or Comprises, as an active ingredient, at least one selected from the group consisting of a pharmacologically acceptable salt of the glycoconjugate, an enzyme involved in the synthesis of the sugar chain, and a nucleic acid encoding the enzyme.
  • a pharmacologically acceptable salt of the glycoconjugate an enzyme involved in the synthesis of the sugar chain
  • a nucleic acid encoding the enzyme a nucleic acid encoding the enzyme.
  • the second invention of the present invention relates to a sugar chain having bisecting GlcNAc, a complex saccharide having the sugar chain in its structure, a derivative of the sugar chain or the complex saccharide, the sugar chain or the complex saccharide.
  • Remedy or prevention for a neurological disease comprising as an active ingredient at least one selected from the group consisting of a pharmacologically acceptable salt of high quality, an enzyme involved in the synthesis of the sugar chain, and a nucleic acid encoding the enzyme.
  • a neurological disease include neurodegenerative diseases, dementia, and brain tumors.
  • the third invention of the present invention relates to a sugar chain having bisecting GlcNAc, a complex saccharide having the sugar chain in its structure, a derivative of the sugar chain or the complex saccharide, the sugar chain or the complex saccharide.
  • Quality and pharmacologically acceptable salts an enzyme involved in the synthesis of the sugar chain, and at least one selected from the group consisting of nucleic acids encoding the enzyme as an active ingredient, having learning and Z or memory ability. It relates to an enhancer or an improver.
  • a fourth invention of the present invention provides a sugar chain having bisecting GlcNAc, a complex saccharide having the sugar chain in its structure, a derivative of the sugar chain or the complex saccharide, the sugar chain or the complex saccharide.
  • the present invention relates to a food or beverage containing at least one member selected from the group consisting of a pharmacologically acceptable salt of high quality, an enzyme involved in synthesizing the sugar chain, and a nucleic acid encoding the enzyme.
  • the food or beverage is a food or beverage used for the treatment or prevention of a neurodegenerative disease, dementia or brain tumor, or the treatment or prevention of the neurodegenerative disease, dementia or brain tumor.
  • a fifth invention of the present invention relates to a sugar chain having bisecting GlcNAc, a complex saccharide having the sugar chain in its structure, a derivative of the sugar chain or the complex saccharide, the sugar chain or the complex saccharide.
  • Neurite outgrowth characterized by administering to a specimen at least one selected from the group consisting of a pharmacologically acceptable salt, an enzyme involved in the synthesis of the sugar chain, and a nucleic acid encoding the enzyme. The method of inducing.
  • R 1 represents a sugar residue, and “ ⁇ ” means the presence or absence of a GlcNAc residue
  • the gist of the present invention is as follows:
  • a neurite comprising as an active ingredient at least one selected from the group consisting of a pharmacologically acceptable salt of a glycoconjugate, an enzyme involved in the synthesis of the sugar chain, and a nucleic acid encoding the enzyme.
  • R 1 represents a sugar residue, and R means the presence or absence of a GlcNAc residue.
  • R 1 represents a sugar residue
  • R 2 and R 3 bind to mannose via a ⁇ 1-2 bond, a ⁇ 1-4 bond or a 1-6 bond.
  • Indicates a GlcNAc residue (however, when R 2 and R 3 have a GlcNAc residue, one or two R 2 and R 3 may be directly bonded to mannose)
  • a neurological disease comprising, as an active ingredient, at least one selected from the group consisting of a pharmacologically acceptable salt of a glycoconjugate, an enzyme involved in the synthesis of the sugar chain, and a nucleic acid encoding the enzyme.
  • R 1 represents a sugar residue, and “ ⁇ ” means the presence or absence of a GlcNAc residue
  • R 1 represents a sugar residue
  • R 2 and R 3 are linked to mannose via a ⁇ 1-2 bond, a ⁇ 1-4 bond or a 1-6 bond.
  • Indicates a GlcNAc residue (however, when R 2 and R 3 have a GlcNAc residue, one or two R 2 and R 3 may be directly bonded to mannose)
  • R 1 represents a sugar residue, and “ ⁇ ” means the presence or absence of a GlcNAc residue
  • a learning or Z or memory improving or improving agent according to the above (8) which is a sugar chain represented by
  • R 1 represents a sugar residue
  • R 2 and R 3 are bonded to mannose via a ⁇ 1-2 bond, a ⁇ 1-4 bond or a 1-6 bond.
  • Indicates a GlcNAc residue (however, when R 2 and R 3 have a GlcNAc residue, one or two R 2 and R 3 may be directly bonded to mannose)]
  • a learning or Z or memory improving or improving agent according to the above (8) which is a sugar chain represented by
  • (11) bisecting a sugar chain having GlcNAc, a complex saccharide having the sugar chain in its structure, a derivative of the sugar chain, a derivative of the complex saccharide, a pharmacologically acceptable salt of the sugar chain, and A food or beverage comprising at least one member selected from the group consisting of pharmacologically acceptable salts of glycoconjugates;
  • R 1 represents a sugar residue, and “1” means the presence or absence of a GlcNAc residue.
  • R 1 represents a sugar residue
  • R 2 and R 3 represent a ⁇ 1-2 bond, a ⁇ 1-4 bond or 1-6
  • a sugar chain having bisecting GlcNAc a complex saccharide having the sugar chain in its structure, a derivative of the sugar chain, a derivative of the complex saccharide, a pharmacologically acceptable salt of the sugar chain, Administering at least one selected from the group consisting of a pharmacologically acceptable salt of a glycoconjugate, an enzyme involved in synthesizing the sugar chain, and a nucleic acid encoding the enzyme.
  • R 1 represents a sugar residue, and “ ⁇ ” means the presence or absence of a GlcNAc residue
  • R 1 represents a sugar residue
  • R 2 and R 3 represent a ⁇ 1-2 bond, a ⁇ 1-4 bond or 1-6 bond.
  • R 1 represents a sugar residue
  • R 2 and R 3 are linked to mannose via a ⁇ 1-2 bond, a ⁇ 1-4 bond or a 1-6 bond.
  • Indicates a GlcNAc residue (however, when R 2 and R 3 have a GlcNAc residue, one or two R 2 and R 3 may be directly bonded to mannose)
  • a sugar chain having a bisecting GlcNAc represented by: a complex saccharide having the sugar chain in its structure, a derivative of the sugar chain, a derivative of the complex sugar, a pharmacologically acceptable salt of the sugar chain, Administering at least one selected from the group consisting of a pharmacologically acceptable salt of the glycoconjugate, an enzyme involved in the synthesis of the sugar chain, and a nucleic acid encoding the enzyme.
  • R 1 represents a sugar residue
  • R 2 and R 3 bind to mannose via a ⁇ 1-2 bond, a ⁇ 1-4 bond or a 1-6 bond, May indicate a GlcNAc residue
  • R 1 represents a sugar residue
  • R 2 and R 3 are linked to mannose via a ⁇ 1-2 bond, a ⁇ 1-4 bond or a 1-6 bond.
  • Indicates a GlcNAc residue (however, when R 2 and R 3 have a GlcNAc residue, one or two R 2 and R 3 may be directly bonded to mannose)
  • a sugar chain having a bisecting GlcNAc represented by: a complex saccharide having the sugar chain in its structure, a derivative of the sugar chain, a derivative of the complex sugar, a pharmacologically acceptable salt of the sugar chain, Use of at least one selected from the group consisting of a pharmacologically acceptable salt of the glycoconjugate, an enzyme involved in synthesizing the sugar chain, and a nucleic acid encoding the enzyme; and
  • R 1 represents a sugar residue
  • R 2 and R 3 are bonded to mannose via a ⁇ 1-2 bond, a ⁇ 1-4 bond or a 1-6 bond.
  • Indicates a GlcNAc residue (however, when R 2 and R 3 have a GlcNAc residue, one or two R 2 and R 3 may be directly bonded to mannose)
  • a sugar chain having a bisecting GlcNAc represented by: a complex saccharide having the sugar chain in its structure, a derivative of the sugar chain, a derivative of the complex sugar, a pharmacologically acceptable salt of the sugar chain, Use of at least one member selected from the group consisting of a pharmacologically acceptable salt of the glycoconjugate, an enzyme involved in the synthesis of the sugar chain, and a nucleic acid encoding the enzyme;
  • the neurite outgrowth inducing agent of the present invention has an excellent effect that a new neural network can be formed based on neurite outgrowth.
  • the therapeutic or preventive agent for a neurological disease of the present invention it is possible to ameliorate the symptoms of a disease accompanied by neurodegeneration, and to suppress the onset or progression of the disease. I do.
  • the learning and Z or memory abilities improver or improving agent of the present invention the learning and Z or memory abilities of an individual animal can be extended, and the learning and Z of a reduced individual due to various factors can be improved. It has an excellent effect that Z or memory ability can be recovered.
  • ADVANTAGE OF THE INVENTION According to the food or beverage of the present invention, an excellent effect is obtained in which ingestion of the food or beverage provides a therapeutic or preventive effect for a neurological disease, and an improvement or improvement effect of learning and Z or memory ability.
  • the method for inducing neurite outgrowth of the present invention there is an excellent effect that it is possible to induce the generation of neurites that differentiate into axons or ⁇ processes and to induce Z or elongation.
  • ADVANTAGE OF THE INVENTION According to the method for treating or preventing a neurological disease of the present invention, it is possible to improve the symptom of a disease accompanied by neurodegeneration and to suppress the onset or progress of the disease. Furthermore, according to the method for improving or improving the learning and Z or memory ability of the present invention, the learning and Z or memory ability of an animal individual can be extended, and the learning and z of an individual who has decreased due to various factors can be improved. Or, it has an excellent effect that the memory ability can be restored.
  • the supply of a medicament suitable for performing the above-mentioned method for treating or preventing a nervous disease, the use of a nervous system It has an excellent effect of enabling treatment or prevention of a disease.
  • FIG. 1 is a diagram showing the neurite outgrowth-inducing effect of Gn (Gn) Gn-W-GP.
  • Gn Gn
  • Open bars indicate nerve extension and black bars indicate cell extension.
  • FIG. 2 is a diagram showing neurite outgrowth in GnT-III gene-transfected cells.
  • the present invention provides a sugar chain having a bisecting GlcNAc (bisecting GlcNAc) structure, a glycoconjugate having the sugar chain structure, and an enzyme relating to the synthesis of the sugar chain, which exhibits an excellent neurite elongation effect. Based on their surprising findings.
  • the present invention relates to a neurite outgrowth inducing agent.
  • the neurite outgrowth inducing agent of the present invention includes a sugar chain having the bisecting GlcNAc, a complex saccharide having the sugar chain in its structure, the sugar chain or a derivative of the complex sugar, the sugar chain or the sugar chain.
  • a major feature is that it contains as an active ingredient at least one selected from the group consisting of a pharmacologically acceptable salt of a glycoconjugate, an enzyme involved in the synthesis of the sugar chain, and a nucleic acid encoding the enzyme.
  • a high neurite outgrowth-inducing effect can be obtained in a site where neurite outgrowth is desired, for example, a site of nerve damage or a site where neurodegeneration is observed.
  • it has an excellent effect that neurites can be efficiently elongated.
  • neurites In the differentiation of undifferentiated neurons, neurites elongate first, and then one of the neurites rapidly elongates to exhibit axonal properties, In addition, the remaining neurites acquire the properties of ⁇ .
  • the axons and dendrites of the cells thus formed form synapses with other cells to form a neural circuit.
  • the neurite outgrowth inducer of the present invention the induced neurite force axons or ⁇ processes are generated, and an excellent effect of promoting the formation of a new neural network is exhibited.
  • the neurite is elongated by extending the neurite. It is possible to regenerate vesicles, treat and prevent neurological diseases such as neurodegenerative diseases, and the like.
  • a sugar chain of a glycoprotein is bound to an asparagine residue of the protein to form an N-glycoside-linked sugar chain (also referred to herein as "N-darican”) and a serine chain of the protein.
  • O-glycoside-linked sugar chains also referred to as “0-darican” linked via the hydroxyl group of the residue or threonine residue.
  • the N-darican has a reducing terminal sugar residue, N-acetyldarcosamine (GlcNAc), bonded to an amino group of asparagine on the peptide chain, and a reducing terminal N-acetyldarcosamine has an anomeric hydroxyl group.
  • N-glycans are further referred to as complex-type sugar chains comprising sugar residues such as sialic acid, galactose, mannose, fucose, and N-acetyl-darcosamine ("N-acetyl-lactosamine-type sugar chains").
  • An oligomannose-type sugar chain comprising mannose (Man) and N-acetyl-darcosamine, and a mixed molding having a structure in which the N-acetyl-lactosamine-type sugar chain and the oligomannose-type sugar chain are combined.
  • Sugar chains also referred to as "hybrid-type sugar chains" are classified into three types.
  • the sugar chain having bisecting GlcNAc in the present invention is a sugar chain classified as the above-mentioned complex type sugar chain or hybrid sugar chain, and the hydroxyl group at the 4-position of the ⁇ -mannose residue of the sugar chain. And a sugar chain having acetylacetylcosamine bonded to glycerol.
  • the sugar chain having a complex type bisecting GlcNAc that can be used in the present invention includes, for example, the following formula (1):
  • R represents a sugar residue
  • ⁇ means the presence or absence of a GlcNAc residue.
  • the sugar chain of the formula (1) is, in other words, the following formula (2): [0060] [Formula 17]
  • R 1 represents a sugar residue
  • R 2 and R 3 bind to mannose (Man) via a ⁇ 1-2 bond, a ⁇ 1-4 bond or a 1-6 bond.
  • Man mannose
  • R 1 represents an arbitrary sugar residue
  • R 2 represents a GlcNAc residue which may be bound to mannose (Man) via a ⁇ 1-6 bond or a ⁇ 1-4 bond
  • R 3 represents a GlcNAc residue which may be bound to mannose (Man) via a j81-4 bond or
  • R 1 represents a sugar residue
  • a sugar chain having a four-chain structure represented by is exemplified.
  • a sugar chain having a double-chain structure can be preferably used from the viewpoint of ease of production.
  • the sugar chains used in the present invention include, in addition to the complex type sugar chains described above, bisecting GlcN Mixed sugar chains having Ac are also exemplified.
  • Examples of the hybrid sugar chains having Neusecting GlcNAc used in the present invention include sugar chains having a double-chain structure, sugar chains having a triple-chain structure, sugar chains having a 4-chain structure, and the like.
  • sugar residue represented as R 1 in the sugar chain represented by the formula (1) to (7) for example, G1 CNAC residue, glucose residue, fucose residue, a sialic acid residue Group, N-acetylgalatatosamine residue, galactose residue, mannose residue, N-acetylmannosamine residue, xylose residue and the like.
  • R 2 and R 3 in the sugar chain represented by the formula (2) shows the GlcNAc residues.
  • R 2 and R 3 may be bonded to a mannose residue via a j8 1-2 bond,
  • R 2 is present in the sugar chain represented by the formula (2), one or two R 2 can be bonded to one mannose residue. Two R 2 are, when attached to one mannose residue, wherein the two R 2 may bind to a mannose residue at different binding modes.
  • R 3 when R 3 is present in the sugar chain represented by the formula (2), the R 3 also has one or two Rs per one mannose residue similarly to the R 2. 3 forces can be combined. Also, two R 3, when attached to one mannose residues, as well as the R 2, the two R 3 binds to mannose residues in different binding modes.
  • the sugar chain having bisecting GlcNAc used in the present invention is a sugar chain in which the non-reducing terminal side of the sugar chain is further modified with galactose, sialic acid, fucose, glucuronic acid, GlcNAc, mannose, or the like. Is also good.
  • the glycoconjugate having a bisecting GlcNAc in its structure is a glycoconjugate having a bisecting GlcNAc added to any protein, peptide, lipid, or the like.
  • glycoconjugates having a sugar chain having Neusecting GlcNAc in the structure used in the present invention include glycopeptides, glycoproteins, glycolipids and the like.
  • As a method for producing a sugar chain having bisecting GlcNAc or a complex carbohydrate having the sugar chain in its structure hereinafter, referred to as "sugar chain or complex carbohydrate having bisecting GlcNAc" used in the present invention.
  • GlcNAc N-acetyl darcosamyltransferase ⁇ (also referred to herein as “GnT-III”).
  • glycoprotein When a glycoprotein is obtained as the glycoconjugate used as the substrate, a known method for producing a glycoprotein can be used. For example, calf serum fetuin, transferrin, ⁇ -globulin and the like can be produced by a known method.
  • glycoprotein described above is subjected to limited protein hydrolysis using an enzyme such as a protease such as trypsin, lysyl endopeptidase, or chymotrypsin.
  • an enzyme such as a protease such as trypsin, lysyl endopeptidase, or chymotrypsin.
  • a glycoprotein is degraded by a protein-limited hydrolysis with a protease, an enzymatic reaction is performed in a dialysis membrane or an ultrafiltration membrane, whereby the glycopeptide produced by the degradation with the enzyme can be easily separated.
  • Purification of the target glycopeptide from the mixture of degraded peptides, degraded peptides and glycopeptides by purification methods such as centrifugation, gel filtration, ion exchange chromatography, hydrophobic chromatography, and lectin affinity chromatography can do.
  • the target glycopeptide can be purified from the yolk portion by a purification means such as solvent extraction, centrifugation, gel filtration, ion exchange chromatography, hydrophobic chromatography, and lectin affinity chromatography.
  • glycopeptide from an egg After adding the same amount of water to the chicken egg yolk, add 1 to 10 phenol-water (9: 1) mixture and stir well. Incidentally Then, the obtained mixture is subjected to centrifugation to collect the supernatant. After concentrating the obtained supernatant, gel filtration chromatography using Sephadex G-50 is carried out to obtain a fraction which is positive by the neutral sugar color reaction by the phenol sulfate method. As a result, a glycopeptide having a double-stranded complex type sugar chain can be obtained.
  • the structure of the glycopeptide (SEQ ID NO: 1) thus obtained is shown in the following formula (8).
  • the glycoprotein power of the calf serum futein , transferrin , ⁇ -globulin and the like is also measured by a chemical method such as hydrazinolysis ⁇ glycopeptidase ⁇ (almond).
  • Can release chains (Glycoprotein sugar chain research method, Biological Chemistry Experimental Method 23, published by Gakkai Shuppan Center, 1989).
  • sialic acid, galactose residue or fucose residue is removed from these non-reducing ends. I do.
  • a known method may be used to remove the sugar residue at the non-reducing end.
  • sialic acid may be removed in a dilute solution of an inorganic acid such as dilute hydrochloric acid or dilute sulfuric acid at 50 ° C.
  • Sialic acid is liberated by heating at 100 ° C for 10 minutes to 2 hours, preferably in a 0.025-0.1N hydrochloric acid solution or a 0.025-0.1N sulfuric acid solution at 80 ° C for 1 hour. This can be done.
  • a sialic acid residue, a galatatose residue, a fucose residue and the like are removed by an enzymatic treatment with sialidase, galactosidase, fucosidase or the like.
  • sialidase, galactosidase, fucosidase or the like is a suitable substrate for GnT-III.
  • sialidase used here examples include sialidase derived from Arthrobacter ureafaciens and Clostridium nofringe. Enzymes having a wide substrate specificity such as sialidase derived from Clostridium perfringens are preferably used.
  • the galactosidase for example, an enzyme having a wide substrate specificity such as j8-galactosidase derived from peanut beans and j8-galactosidase derived from Aspergillus niger is preferably used.
  • fucosidase for example, a-fucosidase derived from Streptomyces sp. 142 (Streptomyces sp. 142) strain, ⁇ -fucosidase derived from sea urchin kidney and the like can be used.
  • GlcNAc is enzymatically introduced by allowing GnT-III to act together with UDP-GlcNAc on the thus obtained sugar chain or glycoconjugate having GlcNAc at the non-reducing end.
  • N-acetyl darcosaminyltransferase IV also referred to as “GnT-IV” in the present specification
  • N-acetyl darcosamyl-transferase V in the present specification, “GnT-V )
  • UDP-GlcNAc to obtain various sugar chains or complex carbohydrates having a three- or four-chain structure.
  • the purified enzymes described in Patent No. 2789283, JP-A-6-197756, WO 98Z26053 and the like can be used.
  • nucleic acid encoding GnT-IV (gene), nucleic acid encoding GnT-V (gene)
  • nucleic acid (gene), respectively.
  • an expression vector for an animal cell having a neomycin resistance gene containing a construct in which a GnT- ⁇ gene, a GnT-IV gene, or a GnT-V gene is linked downstream of the actin promoter is used for B16 melanoma cells and rat.
  • Transfected cells such as PC12 cells derived from adrenal pheochromocytoma by the electoporation method or lipofectamine, etc., and the resulting cells are screened for GnT- by screening for transformed cells using G418 resistance as an index.
  • Cells expressing III, GnT-IV or GnT-V are obtained.
  • the obtained cells are subjected to sonication, and the supernatant obtained by removing insolubles by centrifugation can be used as a crude enzyme solution.
  • the sugar chain compound used in the present invention and its derivative were synthesized by an enzyme reaction using the crude enzyme solution or the purified enzyme.
  • examples of the sugar chain or complex saccharide having Neusecting GlcNAc include a sugar chain or complex saccharide having a non-reducing terminal force SGlcNAc.
  • the sugar chain or complex saccharide having bisecting GlcNAc is a sugar chain or complex saccharide whose non-reducing terminal is appropriately modified with fucose, galactose, sialic acid, glucuronic acid, GlcNAc, mannose, or the like. It may be quality.
  • sugar chains or conjugates containing bisecting GlcNAc obtained from natural products are included in the sugar chains and complex saccharides having Neusecting GlcNAc used in the present invention.
  • Carbohydrates are also included.
  • a lectin that specifically binds to a sugar chain having bisecting GlcNAc such as kidney bean lectin (E4PHA). The method is exemplified.
  • a glycoprotein having bisecting GlcNAc obtained by a known method for example, ⁇ -daltamyl transpeptidase, ⁇ globulin, etc.
  • a glycoprotein having bisecting GlcNAc obtained by a known method for example, ⁇ -daltamyl transpeptidase, ⁇ globulin, etc.
  • a sugar residue on the non-reducing terminal side is not particularly limited.
  • a GlcNAc residue, a galactose residue, a sialic acid residue, a fucose residue, Any sugar residue such as a mannose residue may be used.
  • the sugar chain or complex carbohydrate having Neusecting GlcNAc used in the present invention may be a sugar chain or complex carbohydrate produced by synthesis.
  • a sugar chain or complex carbohydrate derivative having the above-mentioned bisecting GlcNAc can be used as long as it exhibits a neurite elongation effect.
  • examples of the derivative include conjugates obtained by modifying the sugar chain or complex saccharide within a range in which the desired activity, that is, the neurite elongation effect is not lost.
  • the modification includes, but is not particularly limited to, the introduction of a non-natural type sugar residue, Examples thereof include addition of a ligated compound or ligands (such as biotin and histidine-tag) and immobilization to a carrier.
  • the derivative in the case of a sugar chain derivative, for example, can be obtained by binding the reducing end to a compound having an amino group by a reductive amination reaction.
  • a reductive amination reaction for example, in order to impart a hydrophobic property to a sugar chain, an aliphatic amine, sphingosine, phosphatidylethanolamine, or the like is bound via the reducing end of the sugar chain. Is also good.
  • derivatives of glycoconjugates for example, a fatty acid, biotin, or the like is bound by utilizing the amino group or the N-terminal amino group of a lysine residue in the peptide moiety. Derivatives can be obtained.
  • the reducing terminal is a fluorescent substance such as 2-aminopyridine-pyrene hydrazine.
  • the resulting labeled product was analyzed by HPLC or the like, and in the case of complex carbohydrates, for example, glycopeptides, the peptide portion was labeled with a fluorescent substance such as dansyl ore, FITC, etc.
  • the yield and purity can be confirmed by analyzing the labeled product by HPLC or the like.
  • such a labeled substance is also included in the derivative used in the present invention. Further, by determining the molecular weight by performing LC-MS analysis or TOF-MS analysis, the structures of the sugar chains, glycoconjugates, and derivatives thereof used in the present invention can be confirmed.
  • the sugar chains, glycoconjugates and derivatives thereof having bisecting GlcNAc used in the present invention can be in the form of a salt in order to improve stability and solubility in water.
  • a salt such as a sodium salt, a potassium salt, a calcium salt, an ammonium salt, a chloride, and a carbonate.
  • the salt of the sugar chain, the salt of the complex saccharide or the salt of a derivative thereof can be used, for example, for general desalting such as Dowex 50W, trade name: Dowex MR3 (both manufactured by Dow Chemical Company). It can be obtained as free sugar chains, complex carbohydrates or derivatives thereof by using ion-exchange resin, and is more likely to be exchanged with other salts.
  • the effect of inducing neurite outgrowth by the neurite outgrowth inducing agent of the present invention is, for example, nervous system cells, preferably, for example, neuroblastoma cells, pheochromocytoma cells, and glia.
  • the cell tumor is evaluated by culturing the cell tumor cells in the presence of a sample to be tested, and observing the obtained cells. It is an indicator of having an induction effect.
  • the effect on cell spreading can be evaluated by the same method.
  • human neuroblastoma cell line SK- such as mouse neuroblastoma cell line Neuro-2a cell (ATCC CCL-131).
  • C6 a rat astroglioma cell line, such as N-SH cells (ATCC HTB 11), SH-SY5Y cells, and rat chromaffin cell tumor cell line 1 ⁇ 12 cells (81-1 CRL1721) Cells (ATCC CCL-107) and the like.
  • the conditions for culturing the nerve cells are not particularly limited. 0.01% by weight of poly-L lysine in Dulbecco's modified Eagle's medium (DMEM) containing 10% by weight of sera and 5% by weight of FCS is used. Conditions include inoculating a coated culture dish into 1 ⁇ 10 5 Z dishes and culturing at 37 ° C. in the presence of 5% by volume CO.
  • DMEM Dulbecco's modified Eagle's medium
  • the concentration of the test sample in the medium can be appropriately set.
  • neurites in cells can be observed by, for example, a phase contrast microscope or the like.
  • a cell having two or more neurites of 3 m or more is a “cell having a neurite”, and a cell having low brightness when observed with a phase contrast microscope is “extended”. Cells ".
  • the neurite outgrowth inducing agent of the present invention may be evaluated for its ability to induce differentiation into cells.
  • the differentiation-inducing ability is determined by culturing the nervous system cells in the presence of a sample to be tested, and examining the obtained cells by using various markers that serve as indicators of cell sorting, for example, Nippon Filament H or the like. It can be evaluated by measuring the presence or absence of expression.
  • the bisecting GlcNAc-containing sugar chains, glycoconjugates, derivatives thereof and Z or salts thereof (hereinafter sometimes referred to as the active ingredient of the present invention) used in the present invention have a neurite elongation activity.
  • Neurite outgrowth agent that is, neurite outgrowth inducer
  • Said neurological disease means a disease accompanied by neurodegeneration, for example, a brain tumor (e.g., accompanied by nerve damage, deterioration of nerve function). Brain tumors); neurodegenerative diseases such as Aln's disease, Parkinson's disease, Huntington's disease, Creutzfeldt-Jakob disease, amyotrophic lateral sclerosis; dementia; and diseases such as cerebral ischemic injury.
  • an enzyme involved in the synthesis of a sugar chain having the bisecting GlcNAc and a nucleic acid encoding the enzyme can also be used as the active ingredient.
  • the enzyme include, but are not limited to, GnT- ⁇ and the like.
  • the nucleic acid encoding GnT— ⁇ include a nucleic acid encoding rat-derived GnT-III [Journal of Biological Chemistry, Vol. 267, pp. 18199 to 18204, 1992] and a human-derived GnT III. [Journal of Biochemistry, Vol. 113, pp. 692-698, 1992].
  • a sugar chain having bisecting GlcNAc is synthesized in cells to which the GnT-III has been administered, thereby exerting an excellent effect of expressing a neurite elongation effect.
  • the nucleic acid encoding GnT-III in a cell to which the nucleic acid encoding GnT-III is administered, the nucleic acid is translated into the nucleic acid GnT-III, and the sugar having bisecting GlcNAc is converted by the GnT-III. Chains are synthesized, thereby exerting an excellent effect of expressing a neurite elongation effect.
  • the present invention relates to an agent for treating or preventing a neurological disease, an agent for treating or preventing dementia, an agent for improving and improving learning and Z or memory ability.
  • the present invention relates to a method for producing a therapeutic or prophylactic agent for a neurological disease, a therapeutic or prophylactic agent for dementia, an agent for improving or improving learning and Z or memory ability, and the like.
  • a sugar chain having the bisecting GlcNAc in particular, a sugar chain represented by the formula (2), a complex saccharide having the sugar chain in its structure, a derivative of the sugar chain, a derivative of the complex saccharide, and the sugar At least one selected from the group consisting of a pharmacologically acceptable salt of a chain, a pharmacologically acceptable salt of the glycoconjugate, an enzyme involved in the synthesis of the sugar chain, and a nucleic acid encoding the enzyme About the use of
  • the neurite can be elongated by the sugar chains, glycoconjugates, derivatives thereof and Z or salts thereof having the above-mentioned Neusecting GlcNAc, so that neurites can be elongated in individuals, for example, humans, non-human animals, etc. Treatment or prevention of neurological disorders, learning and improvement of z or memory ability or Can be improved.
  • the therapeutic or preventive agent for neurological diseases are commonly used in injections, oral preparations, ointments and the like. hand
  • the preparation form is preferably administered directly to the affected area as an injection.
  • a buffer solution such as PBS, a pH-adjusted preparation, physiological saline, a stabilizer, etc. are added to the sugar chain derivative of the present invention, and intravenous, intradermal, subcutaneous, and muscle An injection for intravenous administration can be prepared.
  • the neurite outgrowth inducing agent, the therapeutic or preventive agent for a neurological disease, the enhancer or improver for learning and Z or memory ability of the present invention comprises a sugar chain having bisecting GlcNAc, and the sugar chain in the structure. At least one selected from the group consisting of a complex carbohydrate, a sugar chain or a derivative of the complex carbohydrate, and a pharmacologically acceptable salt strength of the sugar chain or the complex carbohydrate as an active ingredient If it contains, the dosage varies depending on the patient (eg, body weight, age, medical history, etc.) and indications. For example, as an injection, the dose of the active ingredient is from 0.001 to the LOO mg. So, it is preferable to administer.
  • a therapeutic or prophylactic agent for a neurological disease, an enhancer or improver of learning and Z or memory ability GnT-III as an active ingredient, to a cell can be administered by a method used for known protein drugs, for example, by administering to a target cell or a tissue around the target cell as an injection.
  • the neurite outgrowth inducing agent, the therapeutic or preventive agent for a neurological disease, the enhancer or improver for learning and Z or memory ability of the present invention comprises a nucleic acid encoding GnT-III as an active ingredient.
  • administration to cells can be performed by known gene transfer methods.
  • Examples of the gene transfer method include a calcium phosphate method, a microinjection method; a physicochemical method such as an electoral poration method, a lipofection method, and a ribosome method; adenovirus, SV40 virus, and simple virus.
  • Examples include a method using a virus vector such as a virus, an adeno-associated virus, a retrovirus, and a lentivirus.
  • a DNA fragment containing the nucleic acid or a vector into which the nucleic acid is inserted, such as a plasmid vector is introduced into cells. Hope for continuous effect In this case, it is preferable to use a virus vector having a property of integrating a target gene such as an adeno-associated virus, a retrovirus, or a lentivirus into a chromosome.
  • the neurite outgrowth agent of the present invention for a living body a therapeutic or preventive agent for brain tumor 'neurodegenerative disease' dementia, cancer and malignant tumor, and an enhancer or improver for learning and Z or memory ability are As a DNA fragment containing a nucleic acid as an active ingredient, or a nucleic acid incorporated into an appropriate vector, it may be administered to a site where administration is desired, or cells into which the nucleic acid has been introduced may be implanted at a site where administration is desired. You can.
  • GnT-III or a nucleic acid encoding GnT-III is administered to cells in the vicinity of cells where neurite outgrowth is desired (target cells), it may not be administered to target cells.
  • the object of the present invention can be achieved because the neurite outgrowth effect is exerted even on the target cell having the sugar chain force having Neusecting GlcNAc generated in the cells surrounding the cell.
  • the therapeutic or preventive agent for neurological diseases of the present invention comprises a sugar chain having bisecting GlcNAc, a complex carbohydrate having the sugar chain in its structure, the sugar chain or a derivative of the complex carbohydrate, the sugar chain or It is preferable that at least one selected from the group consisting of a pharmacologically acceptable salt of the glycoconjugate, an enzyme involved in the synthesis of the sugar chain, and a nucleic acid encoding the enzyme is contained as an active ingredient.
  • a pharmacologically acceptable salt of the glycoconjugate an enzyme involved in the synthesis of the sugar chain
  • a nucleic acid encoding the enzyme is contained as an active ingredient.
  • the pharmacological evaluation of the therapeutic agent or prophylactic agent for a neurological disease of the present invention includes, for example, an evaluation method in an in-vivo mouth by the same method as the evaluation of the inducing effect of neurite outgrowth; an evaluation method using a neurological disease model animal ; Analysis by positron emission tomography in individuals with neurological disease; Measurement of brain function by magnetoencephalography in individuals with neurological disease; Functional analysis by drawing magnetic resonance function in individuals with neurological disease It can be.
  • Evaluation methods using neurological disease model animals include, for example, administering a drug to be evaluated to model animals such as mice, rats, rabbits, dogs, monkeys, etc., and examining changes in disease-based physiological indices in the model animals.
  • Diagnosing changes in Z or biochemical indicators, anatomy It is performed by observing a diseased part by a typical examination.
  • the physiological index and the Z or biochemical index are determined based on the physiology of a normal animal serving as a source of the neurological disease model animal (ie, an individual substantially not suffering from a neurological disease).
  • the disease state at the diseased site is the same as the corresponding site in the normal animal, etc. It is an indicator of having a therapeutic or preventive effect on the disease.
  • analysis by positron emission tomography shows that, at the site of disease, for example, the turnover of neurotransmitters, such as donotamine, This can be done by analyzing the reuptake site and the like.
  • the turnover or the like shows the same state as the corresponding site in a normal individual, it becomes an index that the drug to be evaluated has a therapeutic or preventive effect for a neurological disease.
  • the agent for improving or improving the learning and / or memory ability of the present invention is a sugar chain having bisecting GlcNAc, a complex saccharide having the sugar chain in its structure, or a complex of the sugar chain or the complex saccharide. At least one selected from the group consisting of a derivative, a pharmacologically acceptable salt of the sugar chain or the glycoconjugate, an enzyme involved in synthesizing the sugar chain, and a nucleic acid encoding the enzyme as an active ingredient There is one major feature in its inclusion. Therefore, according to the agent for improving or improving the learning and Z or memory ability of the present invention, neurite outgrowth is induced in an individual in need of improving or improving the learning and Z or memory ability, and thereby the learning is improved. And Z or memory ability can be improved or improved.
  • improvement of learning and Z or memory ability refers to the level of learning and Z or memory ability that is normally exerted by normal individuals, for example, humans and non-human animals. This means that the level is substantially increased.
  • improved of learning and Z or memory ability refers to an individual who has substantially lost learning and Z or memory ability due to a neurological disease, cerebral ischemic injury, trauma, etc., or has reduced learning and Z or memory ability. In an individual is meant to substantially increase the level of learning and Z or memory capacity.
  • the pharmacological evaluation of the learning and Z or memory capacity improving agent or the improving agent of the present invention can be carried out by, for example, an evaluation method using a normal animal, a learning and Z or model animal with low memory capacity, a learning ability, It can be performed by a force test, a memory test, and the like.
  • the evaluation method using the normal animal, the model animal, and the like is, for example, to administer a drug of a test subject to an animal such as a mouse, a rat, a penguin, a dog, or a monkey, and get out of a maze where a bait is placed at a goal point. This can be done by measuring the time several times.
  • the starting point force also has a greater reduction in the time required to reach the goal point where the food is placed.
  • the drug of the subject is learning and
  • the present invention relates to a method for inducing neurite outgrowth.
  • the method for inducing neurite outgrowth of the present invention comprises a sugar chain having bisecting GlcNAc, a complex saccharide having the sugar chain in its structure, a derivative of the sugar chain, a derivative of the complex saccharide, and the sugar chain. At least one selected from the group consisting of a pharmacologically acceptable salt of the above, a pharmacologically acceptable salt of the glycoconjugate, an enzyme involved in the synthesis of the sugar chain, and a nucleic acid encoding the enzyme.
  • a pharmacologically acceptable salt of the above a pharmacologically acceptable salt of the glycoconjugate
  • an enzyme involved in the synthesis of the sugar chain and a nucleic acid encoding the enzyme.
  • One feature is that it is administered to the specimen.
  • Examples of the specimen include cultured cells, nerve tissue, and animal individuals.
  • Examples of the animal individual include a human and a non-human animal.
  • the effect of inducing neurite outgrowth by the induction method of the present invention can be evaluated by the same method as the method of evaluating the effect of inducing neurite outgrowth by the above neurite outgrowth inducer.
  • administration can be carried out in the same manner as in the case of the aforementioned therapeutic agent or preventive agent for neurological diseases.
  • the neurite outgrowth inducer of the present invention may be used.
  • Cultured cells eg, cells of the nervous system, neural progenitor cells
  • nerve tissue in which neurites have been extended by the induction method of the present invention can be used for transplantation for the treatment of neurological diseases.
  • the present invention relates to a method for treating or preventing a neurological disease.
  • the method for treating or preventing a neurological disease provides an individual having a neurological disease or the neurological disease.
  • a sugar chain having the bisecting GlcNAc particularly a sugar chain having the bisecting GlcNAc represented by the above formula (2), is provided to an individual who is likely to suffer from the disease.
  • One feature is that at least one selected from the group consisting of nucleic acids encoding the enzyme is administered.
  • Examples of the individual include a human and a non-human animal.
  • the therapeutic or preventive effect of the method for treating or preventing a neurological disease of the present invention can be evaluated by the same method as the pharmacological evaluation of the therapeutic or prophylactic agent for a neurological disease of the present invention.
  • administration can be performed in the same manner as in the case of the therapeutic or prophylactic agent for a neurological disease of the present invention.
  • the therapeutic or prophylactic agent for a neurological disease of the present invention may be used.
  • the present invention relates to a method for improving or improving learning and Z or memory ability.
  • the method for improving or improving the learning and Z or memory ability of the present invention can be applied to an individual in need of improving or improving the learning ability for the sugar chain having the bisecting GlcNAc, in particular, the formula (2)
  • a sugar chain having the bisecting GlcNAc represented by the formula, a complex carbohydrate having the sugar chain in its structure, a derivative of the sugar chain, a derivative of the complex sugar, and a pharmacologically acceptable sugar chain Providing at least one member selected from the group consisting of a pharmaceutically acceptable salt, a pharmacologically acceptable salt of the glycoconjugate, an enzyme involved in the synthesis of the sugar chain, and a nucleic acid encoding the enzyme.
  • the individual in need of improving or improving the learning ability includes a normal individual, for example, a human, a non-human animal, or the like; and has a substantial learning and Z or memory ability due to a neurological disease, cerebral ischemic injury, trauma, or the like. Individuals who have lost learning and Z or memory ability due to neurological diseases, cerebral ischemic injury, trauma, and the like.
  • the learning and Z or memory capacity improvement or improvement effect of the learning and Z or memory capacity improvement or improvement method of the present invention is based on the learning and Z or memory capacity improver or modifier. It can be evaluated by the same method as the pharmacological evaluation of a good drug.
  • administration can be performed by the same method as that for the therapeutic or preventive agent for a neurological disease of the present invention.
  • the agent for improving or improving the learning and Z or memory ability of the present invention can be used.
  • the present invention relates to a food or beverage.
  • the food or beverage of the present invention includes a sugar chain having bisecting GlcNAc, a complex saccharide having the sugar chain in its structure, a derivative of the sugar chain, a derivative of the complex saccharide, and pharmacology of the sugar chain.
  • a sugar chain having bisecting GlcNAc a complex saccharide having the sugar chain in its structure
  • a derivative of the sugar chain a derivative of the complex saccharide
  • pharmacology of the sugar chain contains at least one (the above-mentioned active ingredient) selected from the group consisting of specifically acceptable salts and pharmacologically acceptable salts of the glycoconjugates. Therefore, the food or beverage of the present invention is extremely useful for ameliorating and preventing the symptoms of the above-mentioned diseases due to its neurite outgrowth action.
  • the food or beverage may be a functional food or a functional beverage (for example, a food for specified health use) indicating that the purpose is to improve or prevent the symptoms of the above-mentioned
  • the food or beverage of the present invention contains the active ingredient, and thus can be used for treating or preventing a neurodegenerative disease, dementia, or brain tumor. Further, since the food or beverage of the present invention contains the active ingredient, it can be used for improving or preventing learning and Z or memory ability.
  • the food or beverage of the present invention includes food or beverage for assisting treatment or prevention of neurodegenerative disease, dementia or brain tumor, and food or beverage for assisting improvement or prevention of learning and Z or memory ability. Beverages are included.
  • containing used for the food or beverage of the present invention includes the meaning of "addition” and / or "dilution”.
  • the term "containing" used for the food or beverage of the present invention refers to an embodiment in which the active ingredient used in the present invention is contained in a food or beverage, and the term “added”
  • the term ⁇ dilute '' refers to adding the active ingredient used in the present invention to the raw material of food or beverage
  • the term ⁇ dilution '' refers to adding the raw material of food or beverage to the active ingredient used in the present invention. Then, the mode is changed.
  • the method for producing a food or beverage of the present invention is not particularly limited. For example, blending, cooking, processing, etc. can be carried out according to general food or beverage production methods, and can be produced by such production methods.If the obtained food or beverage contains the active ingredient, Just fine.
  • the food or beverage of the present invention is not particularly limited as long as it contains the above-mentioned active ingredient.
  • examples thereof include processed cereals (processed flour, processed starches, premixed cascine). Products, vegetables, macaroni, bread, bean jam, buckwheat, fu, rice noodles, harame, packing mochi, etc., processed oils and fats (plastic oils, tempura oil, salad oil, mayonnaise, dressing, etc.) , Processed soybeans (tofu, miso, natto, etc.), processed meats (ham, bacon, pressed ham, sausage, etc.), marine products (frozen surimi, rikamaboko, chikuwa, hampon, satsumaage, tsumire, Streaks, fish ham, sausage, bonito, processed fish eggs, canned fish, boiled tsukudani, etc.), dairy products (raw milk, cream, yogurt, butter, cheese, condensed milk, milk powder, ice cream, etc.
  • the food or beverage of the present invention contains, adds and Z or is diluted with the above-mentioned active ingredient singly or as a mixture of plural kinds thereof, and contains a necessary amount for expressing a neurite elongation effect.
  • Orally ingestible tablets, granules, capsules, etc. Also includes various shapes.
  • the content of the active ingredient in the food or beverage of the present invention can be appropriately selected from the viewpoint of its function and neurite elongation activity.
  • the content is 0.01% by weight or more.
  • it is at least 0.1% by weight, more preferably at least 1% by weight, at most 10% by weight, more preferably at most 5% by weight.
  • the content can be arbitrarily selected within the above range.
  • the food or beverage of the present invention preferably contains an active ingredient contained therein in an amount of 0. OOOOlmg ⁇ : LOOOmgZ kg body weight per day, preferably ⁇ 0. OOOlmg ⁇ : LOOmgZkg body weight per human (for example, adult).
  • More preferred ⁇ 0. OOlmg ⁇ : LO mgZkg should be ingested so that the body weight intake.
  • Such an intake may fluctuate depending on various conditions, and in some cases, an amount smaller than the above-mentioned intake may be sufficient, or in other cases it may be necessary to exceed the range.
  • the food or beverage of the present invention can be evaluated, for example, by an evaluation method using a neurological model animal used for the pharmacological evaluation of the therapeutic or prophylactic agent for a neurological disease of the present invention.
  • a sugar chain having a GlcNAc residue at the non-reducing end and having a three- or four-chain structure, or a complex saccharide having the sugar chain, which is produced by the action of GnT-V has an activity of inhibiting cell migration and movement, and is therefore effective in treating malignant tumors by inhibiting cancer cell invasion and metastasis. It can be used as a therapeutic or metastasis inhibitor.
  • the above-mentioned therapeutic agent or metastasis inhibitor for malignant tumor can be produced according to the therapeutic or preventive agent for neurological diseases of the present invention.
  • the sugar contained in the eluted fraction was analyzed using the phenol-sulfuric acid method (edited by the Biochemical Society of Japan, New Chemistry Laboratory Course, Vol. 3, Carbohydrate I, Glycoprotein (above), p. ), And the second major eluted sugar-positive fraction was collected.
  • the sugar-positive fraction was concentrated to 5 mL using a rotary evaporator.
  • the obtained product was desalted using a Sephadex G-25 (manufactured by Amersham Bioscience) column (2.5 cm ⁇ 52 cm). At this time, 5% by volume of ethanol was used as an eluent.
  • the sugar-positive fractions were collected by measuring the sugar content of each fraction by the phenol sulfate method.
  • the obtained product was concentrated to 5 mL with a rotary evaporator to obtain a concentrated solution.
  • TOYOPEARL DEAE-650M manufactured by Tosoichi Co., Ltd., product number: 07473
  • Fractions were collected.
  • the flow-through fraction was concentrated to 5 mL using a rotary evaporator.
  • the obtained product was desalted using a Sephadex G-25 column (trade name) and lyophilized to obtain SGP.
  • Example 1 The SGP obtained in (1) was dissolved in water so as to be 170 / z mol Zl. 5 mL. To the obtained solution, 45 mg of powder EZ-Link Sulfo-NHS-Biotin (trade name, manufactured by PIERCE, product number: 21217) was added, and the mixture was vigorously stirred immediately and then shaken at room temperature for 1 hour. The obtained mixture was concentrated to 0.5 mL using a centrifugal concentrator.
  • the obtained supernatant was concentrated to 400 L using a centrifugal concentrator.
  • the obtained product is used as a PD-10 desalting column (Amersham Bioscience) Desalinated by the company, product number: 17-0851-01), further loaded onto a cellulose cartridge column (manufactured by Takara Bio Inc., product number: 4404), purified, and crudely purified biotinylated.
  • Gn.Gn-bi-glycopeptide hereinafter, “crudely purified Gn.Gn-bi-GP” was obtained.
  • the structure of Gn.Gn-bi-GP (SEQ ID NO: 1) is shown in the following formula (9).
  • Rat GnT-III cDNA [-Nishikawa, A., et al., Journal of Biological Chemistry, Vol. 267, pp. 18199-18182, 1992] was converted to pCXNII [- ⁇ (Niwa) et al., Gene, Vol. 15, pp. 193-199, 1991] to construct the plasmid pCXNIl / GnT-III.
  • Lipofectamine 2000 (manufactured by Invitrogen, trade number: 11668-019) was used to transfer the above pCXNIlZGnT-m to rat adrenal pheochromocytoma cell line PC12 (ATCC CRL-1721).
  • DMEM Dulbecco's modified Eagle's medium
  • FCS fetal serum
  • PC12 (GnT-III) cells were transfected with the pCXNII and cloned to obtain PC12 (mock) cells.
  • the obtained PC12 (GnT-III) cells were put on three collagen-coated 10 cm dishes (manufactured by Asahi Techno Glass Co., Ltd., product number: 4020-010) and contained 10% by weight of serum and 5% by weight of FCS. Culture in DMEM in the presence of 5% by volume CO at 37 ° C until confluent
  • the medium was discarded and washed with phosphate buffered saline [PBS (-)]. Separate the cells from the dish using a cell scraper and centrifuge at 1500 X g (5000 rpm) for 5 minutes. Separated and cells harvested. The supernatant is discarded, and the obtained cells are supplemented with 200 ⁇ L of PBS (-) containing 10 ⁇ g mL of leupeptin, 10 / zg / mL aprotune, and ImM fluoride methyl sulfol. The mixture was polished and the cells were suspended by pipetting.
  • PBS (-) phosphate buffered saline
  • This cell suspension was subjected to sonication, and the obtained product was centrifuged at 700 ⁇ g for 10 minutes to obtain about 200 L of a supernatant. The resulting supernatant was used as a GnT-III crude enzyme solution.
  • Sample A was diluted 100 times with water. 1) 0.5 M of 0.5M sodium phosphate buffer (pH 7.5) and 0.5 / zL of 10% by volume Nonidet (trade name) PZ40 (NP — 40, Merck, product number: BDH560092L) and 0.5 L of 500 UZ ⁇ L peptide: ⁇ —Glycosidase F (PNGase F, New England BioLabs, product number: P0704S) , twenty five / zL of water was added and reacted at 37 ° C for 24 hours. The resulting reaction solution was boiled for 5 minutes, and centrifuged at 130,00 ⁇ g (14000 rpm) for 5 minutes to obtain a supernatant.
  • PZ40 NP — 40, Merck, product number: BDH560092L
  • PNGase F ⁇ —Glycosidase F
  • PNGase F New England BioLabs, product number: P0704S
  • the total amount of the supernatant was subjected to pyridylamino (PAM-Doll, trade name: GlycoTAG Reagent Kit (manufactured by Takara Bio Inc., trade number: GT500)). And 20 ⁇ L thereof was analyzed by HPLC.In the HPLC, TSKgel ODS-80T (4.6 ⁇ 150 mm, Tosoh Corporation) was used as a column.
  • human small cell lung cancer cell line QG was also purified from GnT-V. .
  • the same reaction as in Example 1- (3) was performed on crude Gn.Gn-W-GP to obtain a sample B.
  • 2 X buffer solution Composition: 250mM MES -NaOH (. PH6 25 ), 400mM GlcNAc, 20mM E DTA '3Na, 1. 0 volume 0/0 Triton TM X-100] was used.
  • Example 1 (3) Under the same conditions as in Example 1 (3), the sample B was analyzed by PNGase F treatment, PA gel and HPLC. Under these conditions, the PA-Gn.Gn-bi-glycan eluted at 7.1 minutes and the PA-Gn.Gn.Gn-tri'-glycan eluted at 5.2 minutes.
  • PA-Gn.Gn.Gn-tri'-sugar chain was not detected from the crudely purified Gn.Gn-bi-GP, whereas 63% of PA-Gn was detected from sample B. .Gn.Gn-tri'-sugar chains were detected.
  • Example 1 200 ⁇ L of GnT- ⁇ crude enzyme solution prepared by the method of (3) was heat-treated at 98 ° C for 5 minutes, and centrifuged at 13000 X g (14000 rpm) for 10 minutes to obtain a supernatant.
  • the obtained supernatant was loaded on a cellulose cartridge column (manufactured by Takara Bio Inc., product number: 4404) to obtain an eluted fraction. This fraction was concentrated by centrifugation to dryness, and dissolved in 200 L of water to obtain Sample C.
  • Sample D was obtained from PC 12 (mock) cells by the same method.
  • a mouse neuroblastoma cell line Neuro-2a (ATCC CCL-131) was suspended in DMEM containing 10% by weight of serum and 5% by weight of FCS, and 0.01% poly-L-lysine was added.
  • FIG. 1 is a diagram showing the ratio of the number of cells having neurites and the number of expanded cells to the total number of cells, and shows the average and standard deviation of three visual fields. Most of the cells showed neurite outgrowth and cell outgrowth in the sample A-added calo section. In contrast, in the sample C-added group, slight neurite formation was observed, but no cell extension was observed.In the sample D-added group, neurite formation and cell extension were hardly observed. Helped.
  • the cells were fixed with formaldehyde-containing PBS for 1.5 minutes. Then 1% by weight Triton TM The mixture was gently shaken at room temperature for 15 minutes in 50 mM Tris-HCl (pH 6.8) containing X-100. Cells were fixed again with 4% by weight paraformaldehyde for 30 minutes at 4 ° C. Cells were washed with PBS and incubated in 50 mM NH Cl for 30 minutes. Next, the cells are
  • Example 3- (1) The same experiment as in Example 3- (1) was performed using human glioma cells T98G (ATCC CRL-1690). However, crudely purified Gn.Gn-b-to-GP, sample A and sample B were used as test samples, and the dilution with PBS (-) containing 10 mM HEPES was made 50-fold. The time from sample addition to formalin fixation was 90 minutes, and observation by a phase-contrast microscope and observation of actin by Alexa 546-phalloidin (Invitrogen) staining were performed.
  • Rat GnT-III cDNA [-Nishikawa, A., et al., Journal of Biological Chemistry, Vol. .
  • the obtained plasmid was introduced into Neuro-2A cells using Ribofectamine 2000 (manufactured by Invitrogen). Thereafter, transformed cells were selected using G418 resistance as an index, and multiple cell lines stably overexpressing GnT-III were established.
  • a cell strain (referred to as Mock) into which a plasmid plasmid pcDNA3.1 containing no GnT- ⁇ cDNA was introduced was established in the same manner.
  • glycopeptide (neurite outgrowth inducing agent) obtained in Example 2 was mixed under sterile conditions with a solution containing sterile physiological saline and an auxiliary for injection, and the mixture was injected into an injection formulation. To obtain a therapeutic or preventive agent for neurological diseases.
  • the therapeutic or preventive agent for a neurological disease is administered to a nerve injury site of an individual. Over time, the motor and speech abilities impaired by the nerve injury and the degree of recovery of response to Z or external force stimuli are assessed.
  • glycopeptide (a neurite outgrowth inducing agent) obtained in Example 2 is mixed with raw materials at the time of producing beverages and foods.
  • the obtained beverage or food is supplied to normal individuals and individuals whose learning ability and Z or memory ability have been reduced due to nerve damage. After that, they will test their learning and memory skills before and after serving the beverage or food and evaluate their performance.
  • the normal individual Improved performance is an indicator that beverages or foods can improve learning and memory skills.
  • the performance of individuals with reduced learning ability and Z or memory ability due to nerve injury after the supply of beverages or foods approaches the normal level compared to before the supply of beverages or foods, the learning ability with the beverages or foods It is an indicator of the effect of improving memory ability.
  • a sugar chain having Neusecting GlcNAc, a glycoconjugate, a derivative thereof, a salt thereof, an enzyme relating to the synthesis of the sugar chain, and a medicament or a reagent containing a nucleic acid encoding the enzyme , Food or beverage is provided.
  • the drug, food or beverage is a neurite outgrowth-inducing effect of sugar chains, glycoconjugates, their derivatives, or Z or their salts having bisecting GlcNAc, thereby treating or preventing neurological disorders, and improving or improving learning and memory ability.
  • the present invention provides a reagent containing the active ingredient and having a neurite outgrowth-inducing action.
  • SEQ ID NO: 1 shows the amino acid sequence of the peptide portion of a glycopeptide.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Présentant un effet d’allongement de neurite élevé, il est prévu un nouvel agent d'allongement de neurite, un agent thérapeutique ou préventif des troubles neurodégénérescents, un aliment ou une boisson pour le traitement ou la prévention de ce trouble, un procédé pour induire un allongement de neurite, un procédé de traitement ou de prévention d’un trouble neurologique, un procédé pour augmenter ou améliorer la capacité d’apprentissage et/ou de mémorisation, l’utilisation d’une chaîne de sucre dans la production de médicament pour le traitement ou la prévention de trouble neurologique et l’utilisation d’une chaîne de sucre dans la production d’un produit augmentant ou améliorant la capacité d’apprentissage et/ou de mémorisation.
PCT/JP2005/006640 2004-04-08 2005-04-05 Agent induisant un allongement de neurite WO2005097155A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006512076A JPWO2005097155A1 (ja) 2004-04-08 2005-04-05 神経突起伸長誘導剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004114417 2004-04-08
JP2004-114417 2004-04-08

Publications (1)

Publication Number Publication Date
WO2005097155A1 true WO2005097155A1 (fr) 2005-10-20

Family

ID=35124834

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/006640 WO2005097155A1 (fr) 2004-04-08 2005-04-05 Agent induisant un allongement de neurite

Country Status (2)

Country Link
JP (1) JPWO2005097155A1 (fr)
WO (1) WO2005097155A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481711B2 (en) 2010-07-06 2013-07-09 Hidenori Kamanishi Neurite outgrowth agent
WO2014208742A1 (fr) * 2013-06-28 2014-12-31 第一三共株式会社 Procédé de purification d'un peptide à base d'oligosaccharides
US9127276B2 (en) 2013-05-01 2015-09-08 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
US9382540B2 (en) 2014-05-01 2016-07-05 Isis Pharmaceuticals, Inc Compositions and methods for modulating angiopoietin-like 3 expression
US10023861B2 (en) 2011-08-29 2018-07-17 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
US10280423B2 (en) 2014-05-01 2019-05-07 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating complement factor B expression
US10557137B2 (en) 2015-11-06 2020-02-11 Ionis Pharmaceuticals, Inc. Modulating apolipoprotein (a) expression
US11400161B2 (en) 2016-10-06 2022-08-02 Ionis Pharmaceuticals, Inc. Method of conjugating oligomeric compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07126185A (ja) * 1993-10-29 1995-05-16 Tonen Corp オリゴ糖を表面に有するリポソーム

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07126185A (ja) * 1993-10-29 1995-05-16 Tonen Corp オリゴ糖を表面に有するリポソーム

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GU J. ET AL.: "beta1,4-N-Acetylglucosaminyl transferese III down-regulates neurite outgrowth induced by costimulation of epidermal growth factor and integrins through the Ras/ERK signaling pathway in PC12 cells.", GLYCOBIOLOGY, vol. 14, no. 2, February 2004 (2004-02-01), pages 177 - 186, XP002994504 *
VOSHOL H. ET AL.: "Structure of the HNK-1 carbohydrate epitope ons peripheral myelin glycoprotein.", J.BIOL.CHEM., vol. 271, no. 38, 1996, pages 22957 - 22560, XP002138942 *
YAZAKI T. ET AL.: "Peripheral myelin p0 protein mediates neurite outgrowth of cortical neurons in vitro and axonal regeneration in vivo.", NEUROSCI.LETT., vol. 176, no. 1, 1994, pages 13 - 16, XP002994503 *
ZAMZE S. ET AL.: "A family of novel, acidic N-glycans in Bowes Melanoma tissue plasminogen activator have L2/HNK-1-bearing antennae, many with sulfation of the fucosylated chitobiose core.", EUR. J.BIOCHEM., vol. 268, no. 14, 2001, pages 4063 - 4078, XP002994502 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481711B2 (en) 2010-07-06 2013-07-09 Hidenori Kamanishi Neurite outgrowth agent
US10023861B2 (en) 2011-08-29 2018-07-17 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
US10883104B2 (en) 2013-05-01 2021-01-05 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein (a) expression
US9932580B2 (en) 2013-05-01 2018-04-03 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating HBV expression
US9127276B2 (en) 2013-05-01 2015-09-08 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
US9181549B2 (en) 2013-05-01 2015-11-10 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
US9181550B2 (en) 2013-05-01 2015-11-10 Isis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein (a) expression
US11299736B1 (en) 2013-05-01 2022-04-12 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
US9145558B2 (en) 2013-05-01 2015-09-29 Isis Pharmaceuticals, Inc. Compositions and methods for modulating HBV expression
US9932581B2 (en) 2013-05-01 2018-04-03 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein C-III expression
US10683499B2 (en) 2013-05-01 2020-06-16 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating TTR expression
US9957504B2 (en) 2013-05-01 2018-05-01 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein (a) expression
US11851655B2 (en) 2013-05-01 2023-12-26 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein (a) expression
US9163239B2 (en) 2013-05-01 2015-10-20 Isis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein C-III expression
JPWO2014208742A1 (ja) * 2013-06-28 2017-02-23 第一三共株式会社 オリゴ糖ペプチドの精製方法
WO2014208742A1 (fr) * 2013-06-28 2014-12-31 第一三共株式会社 Procédé de purification d'un peptide à base d'oligosaccharides
US10280423B2 (en) 2014-05-01 2019-05-07 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating complement factor B expression
US10875884B2 (en) 2014-05-01 2020-12-29 Isis Pharmaceuticals, Inc. Compositions and methods for modulating angiopoietin-like 3 expression
US9382540B2 (en) 2014-05-01 2016-07-05 Isis Pharmaceuticals, Inc Compositions and methods for modulating angiopoietin-like 3 expression
US11732265B2 (en) 2014-05-01 2023-08-22 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating complement factor B expression
US9957292B2 (en) 2014-05-01 2018-05-01 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating angiopoietin-like 3 expression
US10557137B2 (en) 2015-11-06 2020-02-11 Ionis Pharmaceuticals, Inc. Modulating apolipoprotein (a) expression
US11319536B2 (en) 2015-11-06 2022-05-03 Ionis Pharmacueticals, Inc. Modulating apolipoprotein (a) expression
US11400161B2 (en) 2016-10-06 2022-08-02 Ionis Pharmaceuticals, Inc. Method of conjugating oligomeric compounds

Also Published As

Publication number Publication date
JPWO2005097155A1 (ja) 2008-02-28

Similar Documents

Publication Publication Date Title
WO2005097155A1 (fr) Agent induisant un allongement de neurite
KR102493562B1 (ko) hANP-Fc 함유 분자 콘주게이트
Schnaar et al. Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration
JP4583029B2 (ja) 所定の翻訳後修飾を有する蛋白質の製造方法及び製造手段
Jia et al. Expression of ligands for Siglec-8 and Siglec-9 in human airways and airway cells
Wakabayashi et al. A protein associated with toll-like receptor 4 (PRAT4A) regulates cell surface expression of TLR4
Salama et al. No overall hyposialylation in hereditary inclusion body myopathy myoblasts carrying the homozygous M712T GNE mutation
Caron et al. Soluble galactoside-binding vertebrate lectins: a protein family with common properties
Chen et al. Kefir extracts suppress in vitro proliferation of estrogen-dependent human breast cancer cells but not normal mammary epithelial cells
CN106455600A (zh) 含低聚半乳糖和单糖的减乳糖乳产品以及生产方法
CN107080847A (zh) 细胞外靶向药物缀合物
Gagiannis et al. Engineering the sialic acid in organs of mice using N-propanoylmannosamine
CN111356474A (zh) 重组人类酸性α-葡萄糖苷酶
KR20170138920A (ko) Slit-robo 시스템을 이용한 근감소증 예방 또는 치료용 조성물
JP2008501725A (ja) グリカンに特異的な受容体として機能するインテグリンを介したグリコシルホスファチジルイノシトールグリカンシグナル伝達
Guo et al. Relationship between metastasis-associated phenotypes and N-glycan structure of surface glycoproteins in human hepatocarcinoma cells
Yong et al. Neuroprotective effects of lactoferrin in Alzheimer’s and Parkinson’s diseases: A narrative review
CN108472277A (zh) 用于治疗高胱氨酸尿症的组合物和方法
Buetler et al. Glycolaldehyde‐modified β‐lactoglobulin AGEs are unable to stimulate inflammatory signaling pathways in RAGE‐expressing human cell lines
Kobata Glycobiology in the field of aging research—introduction to glycogerontology
JP7294602B2 (ja) 脂肪肝疾患の予防または治療用組成物
Konya et al. Parkinson’s disease-associated mutations in α-synuclein and UCH-L1 inhibit the unconventional secretion of UCH-L1
DUDLEY et al. Lactase phlorhizin hydrolase turnover in vivo in water-fed and colostrum-fed newborn pigs
JP2022522725A (ja) アルブミンと結合したＳｌｉｔ３タンパク質のＬＲＲＤ２を含む骨関連疾患の予防または治療用組成物
Kobata The third chains of living organisms—a trail of glycobiology that started from the third floor of building 4 in NIH

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006512076

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase